Microbicide Trials Network

MTN-007 is a Phase I, randomized, blinded, placebo-controlled safety and acceptability study of tenofovir 1% gel when applied rectally. Participants will be randomized to receive a single dose of tenofovir 1% gel, 2% N-9 gel or a placebo gel that is applied by a clinician at the study site. Participants will return to the clinic one week later, where they will be given a 7-day supply of the study gel. The study will enroll approximately 63 men and women at domestic sites.